Clinical Trial Update: Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical evaluation of the radiopharmaceutical 177Lu-DansyI-PSMA (LNC1011) for metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-DansyI-PSMA (LNC1011)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Metastatic Castration-resistant Prostate Cancer, mCRPC | Phase 1 | Status: COMPLETED